구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Murine autologous anti-CD19 chimeric antigen receptor T cells (Murine autologous anti-CD19 chimeric antigen receptor T cells) Kite, A Gilead Company·CD19 1 trials |
|---|---|
Overview Program | Murine autologous anti-CD19 chimeric antigen receptor T cells |
Overview Company | Kite, A Gilead Company |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Versatile strategy for controlling the specificity and activity of engineered T cells.. The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promising cancer therapy. Despite impressive clinical efficacy, the general application of current CAR-T--cell therapy is limited by serious treatment-related toxicities. One approach to improve … |
Toxicology CRS | Reported |
Clinical Safety signal | Versatile strategy for controlling the specificity and activity of engineered T cells.. The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promising cancer therapy. Despite impressive clinical efficacy, the general application of current CAR-T--cell therapy is limited by serious treatment-related toxicities. One approach to improve … |
Clinical Selected reported efficacy | ORR 88% |
Clinical Reported ORR | 88% |
Clinical Result source | ClinicalTrials.gov NCT04002401 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04002401 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Murine autologous anti-CD19 chimeric antigen receptor T cells (Murine autologous anti-CD19 chimeric antigen receptor T cells) Kite, A Gilead Company·CD19 1 trials |
|---|---|
Overview Program | Murine autologous anti-CD19 chimeric antigen receptor T cells |
Overview Company | Kite, A Gilead Company |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Versatile strategy for controlling the specificity and activity of engineered T cells.. The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promising cancer therapy. Despite impressive clinical efficacy, the general application of current CAR-T--cell therapy is limited by serious treatment-related toxicities. One approach to improve … |
Toxicology CRS | Reported |
Clinical Safety signal | Versatile strategy for controlling the specificity and activity of engineered T cells.. The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promising cancer therapy. Despite impressive clinical efficacy, the general application of current CAR-T--cell therapy is limited by serious treatment-related toxicities. One approach to improve … |
Clinical Selected reported efficacy | ORR 88% |
Clinical Reported ORR | 88% |
Clinical Result source | ClinicalTrials.gov NCT04002401 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04002401 |
추천 비교
추천 비교